Therapy of common superficial fungal infections

Dermatologic Therapy

Volumn 17, Issue 6, 2004, Pages 517-522

  Huang, David B ^a,b   Ostrosky Zeichner, Luis ^b   Wu, Jashin J ^c   Pang, Katie R ^d   Tyring, Stephen K ^e,f  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e University of Texas Health Science Center   (United States)

^f CENTER FOR CLINICAL STUDIES   (United States)

Author keywords

Fungi; Superficial; Therapy

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANIDULAFUNGIN; ANTIFUNGAL AGENT; BETAMETHASONE; BETAMETHASONE DIPROPIONATE; BUTENAFINE; CICLOPIROX; CICLOPIROXOLAMINE; CISAPRIDE; CLOTRIMAZOLE; CORTICOSTEROID DERIVATIVE; DOFETILIDE; ECONAZOLE; FLUCONAZOLE; GRISEOFULVIN; GRISTATIN; HALOPROGIN; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; MICAFUNGIN; MICONAZOLE; MIDAZOLAM; NAFTIFINE; NYSTATIN; OXICONAZOLE; PIMOZIDE; PYRROLE DERIVATIVE; QUINIDINE; SIMVASTATIN; SULCONAZOLE; TERBINAFINE; TOLNAFTATE; TRIAZOLAM; UNINDEXED DRUG; VORICONAZOLE;

CANDIDA; CANDIDIASIS; DERMATOMYCOSIS; DRUG CONTRAINDICATION; EPIDERMOPHYTON; HUMAN; MALASSEZIA FURFUR; MICROSPORUM; MYCOSIS; NONHUMAN; ONYCHOMYCOSIS; REVIEW; SIDE EFFECT; TRICHOPHYTON; TRICHOPHYTON MENTAGROPHYTES; TRICHOPHYTON RUBRUM;

ANTIFUNGAL AGENTS; CANDIDIASIS, CUTANEOUS; DERMATOMYCOSES; DIAGNOSIS, DIFFERENTIAL; HUMANS; ONYCHOMYCOSIS;

EID: 10644276239     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1396-0296.2004.04055.x     Document Type: Review

References (16)

1. Harrell TK, Necomb WW, Replogle WH, King DS, Noble SL. Onychomycosis: improved cure rates with itraconazole and terbinafine. J Am Board Fam Pract 2000: 13: 268-273.
2. Weitzman I, Summerbell RC. The dermatophytes. Clin Microbiol Rev 1995: 8: 240-259.
3. Pierard GE, Arrese JE, Pierard-Franchimont C. Treatment and prophylaxis of tinea infections. Drugs 1996: 52: 209-224.
4. Noble SL, Forbes RC, Stamm PL. Diagnosis and management of common tinea infections. Am Fam Physician 1998: 58: 163-174.
5. Dei Gas E, Vernes A. Parasitic adaptation of pathogenic fungi to mammalian hosts. Crit Rev Microbiol 1986: 13: 173-218.
6. Gupta AK, Einarson TR, Summerbell RC, Shear NH. An overview of topical antifungal therapy in dermatomycoses. A North American perspective. Drugs 1998: 55: 645-674.
7. Wortzel MH. A double-blind study comparing the superiority of a combination antifungal (clotrimazole)/steroidal (betamethasone dipropionate) product. Cutis 1982: 30: 258-261.
8. Katz HI, Bard J, Cole GW, Fischer S, McCormick GE, Medansky RS. SCH 370 (clotrimazole-betamethasone dipropionate) cream in patients with tinea cruris or tinea corporis. Cutis 1984: 34: 183-188.
9. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE. Practice guidelines for the treatment of candidiasis. Infectious Dis Soc Am Clin Infect Dis 2000: 30: 662-678.
10. Smith DE, Midgley J, Allan M, Connolly GM, Gazzard BG. Itraconazole versus ketoconazole in the treatment of oral and oesophageal candidosis in patients infected with HIV. AIDS 1991: 5: 1367-1371.
11. Hay RJ. Overview of studies of fluconazole in oropharyngeal candidiasis. Rev Infect Dis 1990:12: S334-S337.
12. Ruhnke M, Eigler A, Tennagen I, Geiseler B, Engelmann E, Trautmann M. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol 1994: 32: 2092-2098.
13. Saag MS, Fessel WJ, Kaufman CA, Merrill KW, Ward DJ, Moskovitz BL. Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients. AIDS Res Hum Retroviruses 1999:15: 1413-1417.
14. Maki K, Morishita Y, Iguchi Y, et al. In vitro antifungal activity of FK463, a novel water-soluble echinocandin-like lipopeptide. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy 1998. Abstract No. p. 268, abst. no. F-141.
15. Pfaller MA, Messer SA, Coffman S. In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivatives, LY303366, and other antifungal agents. Antimicrob Agents Chemother 1997: 41: 763-766.
16. Uzun O, Kocagoz S, Cetinkaya Y, Arikan S, Unal S. In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrob Agents Chemother 1997: 41: 1156-1157.